Pharsight

1. List of Boniva drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7192938	HOFFMANN LA ROCHE	Method of treatment using bisphosphonic acid	May, 2023 (2 months from now)
US7718634	HOFFMANN LA ROCHE	Method of treatment using bisphosphonic acid	May, 2023 (2 months from now)
US7410957	HOFFMANN LA ROCHE	Method of treatment using bisphosphonic acid	May, 2023 (2 months from now)

Drugs and Companies using IBANDRONATE SODIUM ingredient

Market Authorisation Date: 16 May, 2003

Treatment: Treatment and prevention of osteoporosis in postmenopausal women by once-monthly oral administration of ibandronate sodium monohydrate equivalent to 150mg of ibandronic acid; Treatment and prevention of osteoporosis

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
150 mg	16 May, 2007	8	19 Mar, 2012	06 May, 2023	Deferred
2.5 mg	16 May, 2007	1		06 May, 2023	Extinguished

Strength	Dosage	Availability
EQ 2.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
EQ 150MG BASE	TABLET;ORAL	Discontinued

2. List of Valcyte drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9642911	HOFFMANN LA ROCHE	Pharmaceutical dosage forms comprising valganciclovir hydrochloride	Dec, 2027 (4 years from now)
US8889109	HOFFMANN LA ROCHE	Pharmaceutical dosage forms comprising valganciclovir hydrochloride	Dec, 2027 (4 years from now)

Drugs and Companies using VALGANCICLOVIR HYDROCHLORIDE ingredient

Market Authorisation Date: 28 August, 2009

Treatment: NA

Dosage: FOR SOLUTION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
50 mg/mL	21 Mar, 2011	1		29 Mar, 2015	Extinguished

Strength	Dosage	Availability
50MG/ML	FOR SOLUTION;ORAL	Prescription

3. List of Zelboraf drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8143271	HOFFMANN LA ROCHE	NA	Jun, 2026 (3 years from now)
US7504509	HOFFMANN LA ROCHE	Compounds and methods for development of Ret modulators	Oct, 2026 (3 years from now)
US7863288	HOFFMANN LA ROCHE	NA	Jun, 2029 (6 years from now)
US8741920	HOFFMANN LA ROCHE	Process for the manufacture of pharmaceutically active compounds	Jul, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8470818	HOFFMANN LA ROCHE	NA	Aug, 2026 (3 years from now)
US9447089	HOFFMANN LA ROCHE	Compositions and uses thereof	Jun, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Nov 6, 2024

Drugs and Companies using VEMURAFENIB ingredient

Market Authorisation Date: 17 August, 2011

Treatment: Zelboraf is indicated for the treatment of patients with erdheim-chester disease with braf v600 mutation; Treatment of patients with unresectable or metastatic melanoma with brafv600e mutation as detected by an fda approved test

Dosage: TABLET;ORAL